Replies to post #285063 on Amarin Corp Plc (AMRN)

[couldbebetter]

How ironic, that AMRN, a company that has a medication with FDA
approval to treat CVD, is given absolutely no attention for the
prospect that Vascepa, "MAY BE" a potential treatment option:

1. For people with CVD who never had COVID-19. (Duh!)
2 For people with CVD who are infected with COVID-19. (Double Duh!)
3. For people who may exhibit some indications of CVD who are
in recovery from having been infected with COVID-19.

My point here is that in addition to the CVD market being massive
without COVID-19, should COVID-19 make its way through the world's
entire population much like the common cold does, it "MAY" create
an entirely new population of people with CVD as a result of having
had COVID-19. At some point in the future doctors might be screening
people who have had COVID-19 specifically for signs of CVD or damage
to the Cardiovascular system. For example, if 5% of those people
who have had COVID-19 end up with CVD, perhaps due to systemic
inflammation, especially to the endothelium, Vascepa "MAY BE" a
logical treatment option. (Assuming Vascepa and AMRN are ever taken
seriously by the medical establishment.)

[jessellivermore]

jasbg....

It's called transmission..That is these viruses can change configuration and as they pass through one host to another..The most dramatic example of this was the 1918 Great Influenza...In the early months of the year the virus was so mild that there were debates over whether there was even active virus..Then around July of 1918 the virus underwent a mutation and quickly became the deadly killer that ended the lives of over 50 million people..A great number who were in the productive years of their lives..

":>) JL